Sarepta Therapeutics (SRPT) experienced a significant pre-market plunge of 11.74% on Monday, as investors reacted to news affecting the gene therapy sector. The sharp decline comes amid reports that Vinay Prasad is set to return to his role as the top vaccine regulator at the U.S. Food and Drug Administration (FDA).

Sarepta Therapeutics, a leading biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare diseases, saw its stock price tumble along with other gene therapy developers. The appointment of Prasad, known for his stringent approach to drug regulation, has sparked concerns among investors about potentially tighter oversight in the gene therapy space.

This pre-market movement underscores the sensitivity of biotech stocks to regulatory developments, particularly those involving key FDA positions. As the trading day progresses, market participants will be closely watching for any further statements from Sarepta Therapeutics or industry analysts regarding the potential impact of this regulatory change on the company's ongoing gene therapy programs and approval timelines.